Brief: XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Xoma Royalty

02/12/2024 12:35

Dec 2 (Reuters) - XOMA Royalty Corp  XOMA.O :
    * XOMA ROYALTY ACQUIRES PULMOKINE FOR $20 MILLION ADDING THE
ROYALTY AND MILESTONE INTEREST IN SERALUTINIB, A PHASE 3 ASSET,
TO ITS PORTFOLIO
    * XOMA ROYALTY CORP - POTENTIAL TO NET UP TO $25 MILLION IN
MILESTONE PAYMENTS AND EARN A LOW TO MID-SINGLE DIGIT ROYALTY
    * XOMA ROYALTY CORP - ACQUIRES PULMOKINE FOR $20 MILLION
CASH
PAYMENT AT CLOSE
    * XOMA ROYALTY CORP - PHASE 3 STUDY FOR PULMONARY ARTERIAL
HYPERTENSION IS ONGOING AND IS EXPECTED TO READ OUT IN Q4 OF
2025

Source text:  ID:nGNX6b4Syn 
Further company coverage:  XOMA.O 

 ((Reuters.Briefs@thomsonreuters.com;))